浙江泰林生物技术股份有限公司 第四届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江泰林生物技术股份有限公司(以下简称"公司")第四届监事会第三次 会议于 2024 年 10 月 22 日以电话、书面送达等形式发出通知，并于 2024 年 10 月 29 日在公司会议室以现场举手表决的方式召开。会议应出席监事 3 名，实际 出席监事 3 名。本次会议由胡美珠女士召集和主持。 本次会议的召开符合《中华人民共和国公司法》《公司章程》及有关法律、 行政法规的要求，会议合法、有效。 二、监事会会议审议情况 经与会监事审议，会议通过如下议案: | 证券代码：300813 | 证券简称：泰林生物 公告编号：2024-069 | | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | 具体内容详见公司在中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）发布的《2024 年第三季度报告全文》。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 2 ...

Financial Performance - The company's operating revenue for Q3 2024 reached ¥86,185,149.14, representing a 42.15% increase compared to the same period last year[3] - Net profit attributable to shareholders was ¥4,732,621.73, a significant increase of 351.46% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥4,620,107.19, up 237.63% from the previous year[3] - The basic earnings per share for the quarter was ¥0.04, reflecting a 500.00% increase compared to the same period last year[3] - The total operating revenue for the third quarter of 2024 reached ¥242,467,278.88, an increase of 19.3% compared to ¥203,117,602.42 in the same period last year[15] - The total operating costs for the same period were ¥236,221,850.45, up from ¥193,303,198.02, reflecting a year-over-year increase of 22.2%[15] - The net profit for Q3 2024 was CNY 10,599,894.14, a decrease of 48.9% compared to CNY 20,765,694.34 in Q3 2023[16] - Operating profit for the quarter was CNY 12,850,755.64, down 43.5% from CNY 22,693,621.90 in the same period last year[16] - The total comprehensive income attributable to the parent company was CNY 11,314,672.20, down from CNY 21,311,951.81, a decrease of 46.9%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥962,089,074.17, a decrease of 1.17% from the end of the previous year[4] - The total assets as of September 30, 2024, were ¥962,089,074.17, down from ¥973,507,907.87 at the beginning of the period, a decrease of 1.6%[14] - The total liabilities decreased to ¥306,484,433.68 from ¥323,268,730.54, a reduction of 5.2%[15] - The equity attributable to shareholders of the parent company increased to ¥654,843,177.53 from ¥648,762,936.31, an increase of 0.2%[15] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥20,714,994.54, down 65.58% year-on-year[3] - The cash flow from investment activities saw a significant increase of 369.16% to ¥569,235,804.24, attributed to the continued purchase of financial products after their maturity[8] - The net cash flow from operating activities for Q3 2024 was -20,714,994.54 CNY, compared to -12,510,682.38 CNY in Q3 2023, indicating a decline in operational cash flow[19] - Total cash inflow from investment activities was 569,235,804.24 CNY, significantly higher than 121,351,287.20 CNY in the same period last year[19] - The net cash flow from investment activities was 28,422,441.32 CNY, recovering from a negative cash flow of -22,360,540.85 CNY in Q3 2023[19] - Cash inflow from financing activities totaled 15,645,426.70 CNY, down from 76,588,926.92 CNY in Q3 2023[19] - The net cash flow from financing activities was 4,725,027.41 CNY, compared to 18,243,451.57 CNY in the previous year[19] Shareholder Information - The number of common shareholders at the end of the reporting period was 11,207, with the largest shareholder holding 52.98%[10] - The number of restricted shares held by major shareholders increased to 51,455,196 shares, with specific release dates set for 2024 and 2025[12] Expenses - Operating costs rose by 35.23% to ¥126,295,460.96, attributed to increases in raw materials, labor costs, and manufacturing expenses[8] - Financial expenses surged by 144.47% to ¥3,361,208.48, mainly due to increased interest expenses on convertible bonds[8] - Research and development expenses increased to CNY 49,454,422.64, up from CNY 48,129,064.41, reflecting a growth of 2.7% year-over-year[16] - The tax expenses for the quarter were CNY 1,995,378.01, slightly down from CNY 2,112,940.61 in Q3 2023[16] - Other income decreased to CNY 7,231,506.67 from CNY 13,035,063.95, a decline of 44.5%[16] Government Support - The company received government subsidies amounting to ¥109,348.20 during the quarter, contributing positively to its financial performance[5]

上述专利的取得不会对公司及全资子公司泰林生命科学、泰林分析仪器、 泰林医学工程、泰林医疗器械近期生产经营产生重大影响，但有利于公司及全资 子公司泰林分析仪器、泰林生命科学、泰林医学工程、泰林医疗器械进一步完善 知识产权保护体系，发挥自主知识产权优势，并形成持续创新机制，保持技术领 先地位，提升核心竞争力。 | 证券代码：300813 | 证券简称：泰林生物 公告编号：2024-065 | | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | 浙江泰林生物技术股份有限公司 关于取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰 林生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林分析仪器有限公司 （以下简称"泰林分析仪器"）、浙江泰林医学工程有限公司（以下简称"泰林医 学工程"）、浙江泰林医疗器械有限公司（以下简称"泰林医疗器械"）于近期共 取得了 16 项专利证书，具体情况如下： 序号 专利名称 专利类型 申请号 授权公告日 专利权人 1 一种集 ...

| 证券代码：300813 | 证券简称：泰林生物 公告编号：2024-064 | | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | 浙江泰林生物技术股份有限公司 3、截至 2024 年第三季度末，公司剩余可转换公司债券为 2,009,071 张，剩 余票面总金额为人民币 200,907,100.00 元。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所可转换公 司债券业务实施细则》的有关规定，浙江泰林生物技术股份有限公司（以下简称 "公司"或"泰林生物"）现将 2024 年第三季度可转换公司债券转股及公司总股 本变化情况公告如下： 关于 2024 年第三季度可转换公司债券转股情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、泰林转债（债券代码：123135）转股期限为 2022 年 7 月 4 日至 2027 年 12 月 27 日，最新转股价为 16.40 元/股； 2、2024 年第三季度，共有 520 张"泰林转债"完成转股（票面金额共计 52,000.00 元人民币），合计转为 3 ...

| 证券代码：300813 | 证券简称：泰林生物 | 公告编号：2024-063 | | --- | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | | 浙江泰林生物技术股份有限公司 上述专利的取得不会对公司及全资子公司泰林分析仪器、泰林生命科学、 泰林医学工程近期生产经营产生重大影响，但有利于公司及全资子公司泰林分析 仪器、泰林生命科学、泰林医学工程进一步完善知识产权保护体系，发挥自主知 识产权优势，并形成持续创新机制，保持技术领先地位，提升核心竞争力。 特此公告。 序号 专利名称 专利类型 申请号 授权公告日 专利权人 1 一种液体中无机碳去除方法及结 构 发明 2024106192808 2024/8/2 泰林分析仪器 2 一种镜面冷凝水分活度测试方法 发明 2024107354439 2024/8/23 泰林分析仪器 3 一种重量稀释仪 实用 2023233876764 2024/7/26 泰林生命科学 4 一种用于两虫自动检测的滤膜定 位装置 实用 2023234109882 2024/7/30 泰林生命科学 5 一种悬液式生物指示剂 实用 202323440568 ...

长城证券股份有限公司 | 保荐机构名称：长城证券股份有限公司 | 被保荐公司名称：浙江泰林生物技术股份有 | | --- | --- | | | 限公司 | | 保荐代表人姓名：白毅敏 | 联系电话：0755-83516222 | | 保荐代表人姓名：严绍东 | 联系电话：0755-83516222 | 一、保荐工作概述 2024年半年度跟踪报告 | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 | | 2．督导公司建立健全并有效执行规章制度 | | | 的情况 | | | （1）是否督导公司建立健全规章制度（包 括但不限于防止关联方占用公司资源的制 | 是 | | 度、募集资金管理制度、内控制度、内部审 | | | 计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 按月查询，已查询 6 次 | | （2）公司募集资金项目进展是否与信息披 | 是 | | ...

Financial Performance - The company reported a total revenue of 300 million RMB for the first half of 2024, representing a 15% increase compared to the same period last year[7]. - The net profit for the first half of 2024 was 50 million RMB, which is a 10% increase year-over-year[7]. - The company's operating revenue for the reporting period was ¥156,282,129.74, representing a year-on-year increase of 9.68% compared to ¥142,486,385.37 in the same period last year[12]. - Net profit attributable to shareholders decreased by 71.62% to ¥6,582,050.48 from ¥23,194,022.71 in the previous year[12]. - The total profit for the first half of 2024 was ¥7,208,900, a decrease of 70.91% compared to the previous year, primarily due to rising operating costs and the capitalization of convertible bond interest[47]. - The company's earnings per share (EPS) for the first half of 2024 was ¥0.06, down from ¥0.21 in the same period of 2023[132]. - The company reported a significant reduction in employee compensation payable from ¥25,661,330.25 to ¥12,287,099.98, a decrease of approximately 52%[127]. - The company’s cash and cash equivalents decreased by 9.19% to ¥300,037,604.18, down from ¥396,982,503.20 at the end of the previous year[49]. Research and Development - Research and development expenses increased by 30% in the first half of 2024, reflecting the company's commitment to innovation[7]. - The company has developed 387 technology patents, including 43 invention patents, and has participated in the formulation of 35 national and industry standards[38]. - The company has established a multi-level R&D system, including the TaiLin Research Institute and various specialized research centers, collaborating with renowned institutions to drive technological advancements[32]. - The company is focused on developing new technologies and products to meet market demands, ensuring continuous innovation in its offerings[32]. - Research and development investment rose by 2.23% to ¥31,252,149.65, indicating continued commitment to innovation[46]. Product Development and Launches - The company plans to launch two new products in Q3 2024, focusing on advanced microbial testing technologies[7]. - The company successfully launched new rapid microbial detection equipment and fully automated colony counting workstations during the reporting period, enhancing automation and intelligence in microbial laboratories[21]. - The newly developed live cell imaging system was successfully launched, providing real-time observation of cell morphology and growth parameters[23]. - The company has developed a comprehensive product line that includes microbiological testing instruments and sterile production equipment, enhancing its market competitiveness[44]. - The company has developed an automatic colony counting workstation that integrates constant temperature incubation and automatic counting, utilizing AI visual and neural network algorithms for high accuracy in colony counting[29]. Market and Customer Base - User data indicates a growth in customer base by 20%, reaching 1 million active users by the end of June 2024[7]. - The company aims to expand its market presence through innovative product offerings and strategic partnerships in the biotechnology sector[27]. - The company serves nearly 1,400 pharmaceutical enterprise clients, including well-known companies such as WuXi AppTec and Innovent Biologics[41]. - The company is actively developing marketing strategies to expand its customer base in various sectors, including healthcare and research institutions, while participating in industry exhibitions to boost brand visibility[80]. Financial Strategy and Investments - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[2]. - The total amount of raised funds is CNY 402.06 million, with CNY 11.99 million invested during the reporting period[55]. - The company has decided to terminate the "R&D Center Project" and "Sales Network and Technical Service Construction Project" to mitigate investment risks and better align with market trends[59]. - The company has no derivative investments or entrusted loans during the reporting period, indicating a conservative financial strategy[65][66]. - The company has established a robust investor relations framework, ensuring compliance with legal obligations and facilitating communication with shareholders[89]. Risks and Challenges - The company continues to face risks related to market competition and regulatory changes, which are detailed in the risk management section of the report[2]. - The company is facing risks from industry policy changes, particularly due to the regulatory environment in the pharmaceutical manufacturing sector, which is influenced by national laws and standards like the Chinese Pharmacopoeia and GMP[78]. - The company acknowledges the cyclical nature of fixed asset investment in the pharmaceutical equipment sector, which may experience short-term fluctuations due to regulatory changes[78]. - The company has launched new products targeting the cell therapy and biodegradable testing markets, but may face challenges in market acceptance and competition from increasing numbers of manufacturers[80]. Environmental Responsibility - The company emphasizes a commitment to environmental responsibility, implementing measures to reduce carbon emissions and ensure compliance with environmental regulations[87]. - The company has established a comprehensive environmental management system to monitor and control waste and emissions[87]. - The company has established a distributed photovoltaic power station with a capacity of 610 kW, expected to generate over 600,000 kWh annually, saving over 200 tons of standard coal and reducing CO2 emissions by over 600 tons each year[89]. Corporate Governance - The company prioritizes the protection of shareholder and creditor rights, ensuring reasonable returns on investments while considering sustainable development[88]. - Employee rights are respected, with the company providing a safe working environment and necessary social security benefits[88]. - The company has no significant litigation or arbitration matters during the reporting period, ensuring a stable legal environment for operations[91]. - The company has a structured emergency response plan for potential environmental incidents, ensuring preparedness and risk mitigation[86]. Subsidiaries and Organizational Structure - The company has five wholly-owned subsidiaries and two controlling subsidiaries, focusing on various aspects of life sciences and medical engineering[70]. - The subsidiary Zhejiang Tailin Life Science Co., Ltd. reported a net profit of RMB 12.57 million, contributing significantly to the company's overall performance[69]. - The company has multiple subsidiaries focusing on various sectors including laboratory analysis instruments, medical devices, and environmental protection equipment[72][73][74][75]. Financial Reporting and Accounting Policies - The financial statements are prepared based on the principle of continuous operation, adhering to the relevant accounting standards[154]. - The company’s accounting policies include specific measures for impairment of financial instruments, inventory, and fixed asset depreciation[156]. - The company recognizes financial assets when it becomes a party to the financial instrument contract, measuring them initially at fair value[168]. - The company assesses expected credit losses based on the risk of default, with a weighted average of credit losses calculated for financial instruments[178].

浙江泰林生物技术股份有限公司 | 证券代码：300813 | 证券简称：泰林生物 公告编号：2024-062 | | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | 关于 2024 年半年度募集资金存放与使用情况的专项报告 1. 首次公开发行股票募集资金基本情况 经中国证券监督管理委员会《关于核准浙江泰林生物技术股份有限公司首次 公开发行股票的批复》（证监许可〔2019〕2962 号）核准，并经深圳证券交易 所同意，本公司由主承销商安信证券股份有限公司采用余额包销方式，向社会公 众公开发行人民币普通股（A 股）股票 1,300.00 万股，发行价为每股人民币 18.35 元，共计募集资金 23,855.00 万元，坐扣承销和保荐费用 2,545.00 万元后的募 集资金为 21,310.00 万元，已由主承销商安信证券股份有限公司于 2020 年 1 月 9 日汇入本公司募集资金监管账户。另减除上网发行费、招股说明书印刷费、申 报会计师费、律师费、评估费等与发行权益性证券直接相关的新增外部费用 1,516.45 万元（不含税）后，公司本次募集资金净额为 19,793.55 万元 ...

| | 北 京 沃 锶 达 细 胞 技 术 有 限 公 | | 控制子公司 | 其他应收款 | | 135.00 | | 135.00 拆借款 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 司 | | | | | | | | | | 其他关联方及其附属企业 | | | | | | | | | | | 总计 | | - | - | - | 4,693.40 | 14,069.47 | 11,922.80 | 6,840.07 | - | 法定代表人：叶大林 主管会计工作的负责人：叶星月 会计机构负责人：周文琴 | 非经营性资金占用 | 资金占用 | 占用方与上 | 上市公司核算 | 2024 | 年期初 | 2024 年度占用 | 2024 | 年度占 | 2024 | 年度偿 2024 | 年期末 | 占用形 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | ...

| 证券代码：300813 | 证券简称：泰林生物 公告编号：2024-060 | | --- | --- | | 转债代码：123135 | 转债简称：泰林转债 | 浙江泰林生物技术股份有限公司 第四届董事会第二次会议决议的公告 具体内容详见公司于 2024 年 8 月 29 日在中国证监会指定创业板信息披露网 站巨潮资讯网(http://www.cninfo.com.cn)发布的《2024 年半年度报告全文及 其摘要》。 本议案已经公司审计委员会审议通过。 表决结果：同意 7 票；反对 0 票；弃权 0 票。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江泰林生物技术股份有限公司(以下简称"公司")第四届董事会第二次会 议于 2024 年 8 月 18 日以电话、书面送达等形式发出通知，并于 2024 年 8 月 28 日在公司会议室以现场举手表决的方式召开。会议应出席董事 7 名，实际出席董 事 7 名。本次会议由董事长叶大林先生召集和主持，公司董事会秘书、监事及高 级管理人员列席会议。 本次会议的召开符合《中华人民共和国公 ...